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Dendritic cells (DCs) use pattern recognition receptors to detect microorganisms and activate protective immunity. These cells and receptors are thought to operate in an all-or-nothing manner, existing in an immunologically active or inactive state. Here, we report that encounters with microbial products and self-encoded oxidized phospholipids (oxPAPC) induce an enhanced DC activation state, which we call "hyperactive." Hyperactive DCs induce potent adaptive immune responses and are elicited by caspase-11, an enzyme that binds oxPAPC and bacterial lipopolysaccharide (LPS). oxPAPC and LPS bind caspase-11 via distinct domains and elicit different inflammasome-dependent activities. Both lipids induce caspase-11-dependent interleukin-1 release, but only LPS induces pyroptosis. The cells and receptors of the innate immune system can therefore achieve different activation states, which may permit context-dependent responses to infection. P attern recognition receptors (PRRs) promote immune defenses upon encountering lipopolysaccharide (LPS) and other microbial products, which are collectively known as pathogen-associated molecular patterns (PAMPs). PRRs also recognize self-encoded molecules called damage-associated molecular patterns (DAMPs) (1, 2) . The existence of selfderived PRR ligands complicates our current understanding of PRRs as determinants of self/ nonself discrimination.
Oxidized phospholipids derived from 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC), known as oxPAPC, represent one class of DAMPs. oxPAPC is found in dying cells (3) and can reach concentrations of 10 to 100 mM in damaged tissues (4, 5) . oxPAPC is an LPS mimic that, depending on context, promotes or inhibits Toll-like receptor 4 (TLR4)-dependent inflammation (6) (7) (8) . The existence of LPS and a self-derived LPS mimic provides a model to dissect the activities of PAMPs and DAMPs in innate immunity.
If oxPAPC is truly an LPS mimic, then LPS and oxPAPC should exhibit similar activities. We therefore determined whether oxPAPC activates TLR4 in murine bone marrow-derived macrophages (MF) and dendritic cells (DCs). LPS, but not oxPAPC, induced TLR4 dimerization and endocytosis, MyD88-IRAK4 interactions (i.e., myddosome formation), and expression of the cytokines interleukin (IL)-6, tumor necrosis factor-a (TNFa), IL-1b, and interferon-b (IFN-b) (Fig. 1, A to C, and  fig. S1 , A to C). Furthermore, oxPAPC-treated cells contained undetectable viperin or phosphorylated STAT1, both of which were abundant upon LPS treatment (Fig. 1D and fig. S1D ). These data indicate that oxPAPC cannot activate TLR4.
Some DAMPs only induce cytokine release from cells previously exposed to microbial products. For example, adenosine triphosphate (ATP) activates IL-1b release from cells primed with TLR ligands (9) . We therefore examined IL-1b release from LPS-primed DCs. Interestingly, oxPAPC, similar to ATP, induced the release of cleaved IL-1b from LPS-primed DCs (Fig. 2, A Oxidation of PAPC to oxPAPC generates a heterogeneous mixture of lipids ( fig. S4, A and B) . To determine whether alternative sources of oxPAPC have similar activities, we generated oxPAPC enriched in PEIPC [1-palmitoyl-2-(5,6 epoxyisoprostanoyl)-sn-glycero-3-phosphocholine] ( fig. S4C ), an active component of oxPAPC (10) . Like oxPAPC, PEIPC induced IL-1b release from LPS-primed DCs (Fig. 2B) .
In contrast to the effects on IL-1b release, neither ATP nor oxPAPC influenced the abundance of cell-associated IL-1b (Fig. 2B and fig.  S2C ) or the secretion of TNFa (fig. S2, D and E) . Additionally, when DCs were treated simultaneously with LPS/ATP or LPS/oxPAPC (i.e., no priming), IL-1b release was only induced by LPS/ oxPAPC ( fig. S3B ), suggesting differences in how these DAMPs promote IL-1b release. When the phosphocholine variant 1,2-dimyristoyl-snglycero-3-phosphocholine (DMPC) was used, it could not elicit IL-1b release ( fig. S3C ). In contrast, purified components of oxPAPC (KOdiA-PC, POVPC, or PGPC) elicited IL-1b release ( fig. S3C ). In all cases, LPS-induced TNFa secretion was unaffected ( fig. S3C ). Individual lipids within oxPAPC therefore promote IL-1b release.
Inflammasomes are cytoplasmic protein complexes that trigger IL-1b release (9) . To determine whether IL-1b release is inflammasome-dependent, we examined DCs from apoptosis-associated speck-like protein containing a CARD (ASC) knockout (KO), caspase-1 KO, caspase-1/caspase-11 double (d)KO, or NOD-like receptor family, pyrin domain-containing 3 (NLRP3) KO mice, each of which are defective for inflammasome functions (11, 12) . All of these factors were required for oxPAPC-induced IL-1b release (Fig. 2C) , whereas no inflammasome regulator was required for LPS-induced TNFa secretion ( fig. S2F) .
Interestingly, oxPAPC could not elicit IL-1b release from MFs ( fig. S3A ). To explain this finding, we considered that DCs are better "primed" than MFs because they produce more TNFa than MFs in response to LPS ( fig. S2E ). However, IFN-g-treated MFs were primed as well as DCs, yet they could not respond to oxPAPC ( fig. S3D ). Transfection of oxPAPC elicited IL-1b release from DCs primed with the TLR2 ligand Pam3CSK, but not MFs, whereas LPS transfection of MFs elicited IL-1b release (Fig. 2D ). ATP treatments also revealed differences between MFs and DCs. DCs and MFs die upon LPS/ATP with similar kinetics but release different amounts of IL-1b ( S5 ). We do note, however, that populations of DCs and MFs may exist that exhibit different responses to oxPAPC than those described above.
Further analysis of the mechanisms of inflammasome activation revealed that potassium efflux promoted ATP-induced, but not oxPAPCinduced, IL-1b release ( fig. S6 , A to C). Additionally, oxPAPC did not alter mitochondrial functions ( fig. S6D ).
Caspase-11 is an LPS receptor that promotes IL-1b release by noncanonical inflammasomes (13, 14) . Interestingly, oxPAPC-mediated IL-1b release was largely abolished in caspase-11 KO DCs (Fig. 3A) , whereas ATP-mediated IL-1b release remained intact. TNFa secretion was unaffected by caspase-11 deficiency ( fig. S6E ). Microscopic analysis revealed that oxPAPC and ATP induced the formation of ASC and caspase-1 containing "specks" in LPS-pretreated DCs (Fig. 3B) , albeit with different kinetics (fig. S6F ). These structures are recognized as individual inflammasomes (15), and in the specific case of oxPAPC stimulations, speck formation was caspase-11 dependent (Fig.  3B and fig. S6G ). Caspase-11 is therefore likely required for oxPAPC-induced IL-1b release because it promotes inflammasome assembly in DCs.
SCIENCE sciencemag.org fig. S6H ) by an NLRP3-, ASC-, and caspase-11-dependent process ( fig. S6H) . The TLR9 ligand CpG-DNA also primed DCs for oxPAPC responsiveness ( fig. S6I) . Similarly, oxPAPC, but not DMPC, elicited IL-1b release from an LPS-or CpG-DNA-primed splenic DC line called D1 (16) (fig. S6J ). oxPAPC therefore activates multiple DCs upon encounters with diverse TLR ligands. The finding that multiple TLR ligands prime DCs for oxPAPC responsiveness eliminates the possibility that oxPAPC acts as an LPS carrier to caspase-11.
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We considered that oxPAPC interacts with caspase-11, like LPS (13). Endogenous caspase-11 (but not caspase-3) was captured from DC or immortal bone marrow-derived MF (iMF) lysates through interactions with biotin-LPS or biotinoxPAPC (figs. S4D and S7A and Fig. 3C ). Caspase-11 was not captured by the biotinylated NOD2 ligand muramyl dipeptide (MDP) (Fig. 3C) . oxPAPC displayed a dose-dependent signal with immobilized catalytically inactive caspase-11(C254A) using surface plasmon resonance (SPR), as did LPS (Fig.  3D) . In contrast, DMPC did not bind caspase-11, and oxPAPC did not bind immunoglobulin G (fig.  S7B) Mutation of lysine residues within the caspase-11 CARD (caspase activation and recruitment domain) prevents interactions with LPS (13), as assessed by the ability of biotin-LPS to capture caspase-11 produced in 293T cells ( fig. S7C) . Interestingly, these mutations did not prevent interactions with biotin-oxPAPC ( fig. S7C) . Moreover, the isolated caspase-11 catalytic domain (but not the CARD) retained the ability to bind biotinoxPAPC ( fig. S7D ). SPR analysis verified these results, because nearly identical affinities of oxPAPC for caspase-11 or the catalytic domain (noted as DN59) were calculated (Fig. 3D) . LPS could not bind the caspase-11 catalytic domain (Fig. 3D) , as expected (13) . These data establish that distinct domains within caspase-11 bind LPS and oxPAPC.
The interaction of oxPAPC with the catalytic domain prompted us to examine caspase-11 enzymatic activity. Whereas LPS strongly increased activity of caspase-11 monomers, oxPAPC displayed minimal activity (fig. S7E ). We also examined preexisting caspase-11 oligomers, where intrinsic activity is high ( fig. S7E ). Interestingly, whereas LPS stimulated this activity further, oxPAPC suppressed intrinsic activity ( fig. S7E ). Moreover, oxPAPC blocked LPS-induced caspase-11 activity in a dose-dependent manner (fig. S7F ). These data indicate that LPS promotes, but oxPAPC prevents, caspase-11 activity.
To determine whether caspase-11 activity is required for oxPAPC-induced IL-1b release, we reconstituted caspase-11 KO DCs with wild-type (WT) or catalytic mutant (C254A) caspase-11 or empty vector. LPS elicited IL-1b release from cells expressing WT caspase-11 but not empty vector or mutant caspase-11 (Fig. 3F) . These data confirm that caspase-11 activity promotes LPS-induced IL-1b release (17, 18) . Interestingly, WT and mutantreconstituted DCs released IL-1b in response to oxPAPC (Fig. 3F) . TNFa release was unaffected under all conditions ( fig. S7G) . Two modes of caspase-11-mediated IL-1b release therefore exist, with catalytic activity only being necessary for LPS responses.
In addition to caspase-11, oxPAPC-induced IL-1b release requires caspase-1 (Figs. 2C and 3A) . Interestingly, independent of caspase-11, biotinoxPAPC captured endogenous caspase-1 from cell lysates, whereas biotin-LPS could not ( fig. S7 , H and I). These data support a model whereby oxPAPC and LPS promote inflammasome formation via distinct mechanisms, with oxPAPC specifically forming a caspase-1/11 heterocomplex that may promote IL-1b release. The precise mechanisms that govern oxPAPC-caspase interactions, and how these interactions promote inflammasome activities, await further investigation.
Pyroptosis, another inflammasome-dependent activity (19) , is characterized by the loss of plasma membrane integrity and the release of cytoplasmic proteins and organelles. Caspase-11 activity was necessary for transfected LPS to induce pyroptosis, as assessed by lactate dehydrogenase (LDH) release from the cytosol (Fig. 3F) . Surprisingly, oxPAPC did not elicit pyroptosis (Fig. 3F) . We explored this observation further in WT DCs, where LPS/ATP or transfected LPS induced pyroptosis with differing kinetics (Fig. 4A) . Interestingly, although LPS transfection or oxPAPC treatment induced similar amounts of IL-1b release (Fig.  4B) , only LPS transfection caused pyroptosis ( Fig. 4A and fig. S8A ).
To corroborate these observations, we examined plasma membrane integrity of individual cells containing ASC specks. Cells treated with SCIENCE sciencemag.org LPS/ATP contained specks, and these cells lost mitochondria and stained positive for Zombie dye, a cytoplasmic stain (Fig. 4, C and D) . In contrast, cells treated with LPS/oxPAPC contained specks but retained functional mitochondria and displayed minimal Zombie staining (Fig. 4, C and D) . These data indicate that oxPAPC-induced inflammasomes do not promote pyroptosis and suggest that oxPAPC promotes IL-1b release from living cells. Moreover, not only does oxPAPC not induce pyroptosis, this lipid counteracted the slow-acting death pathways activated by LPS (20) (fig. S8B ). Because oxPAPC promotes DC viability and IL-1b promotes T cell activation (21, 22) , we examined whether oxPAPC displayed adjuvant activity. WT, caspase-11, and caspase-1/-11 dKO mice were injected subcutaneously with LPS, ovalbumin (OVA), and/or oxPAPC that was emulsified in incomplete Freund's adjuvant (IFA). After 40 days, CD4 + T cells were isolated from draining lymph nodes and exposed to DCs that were pulsed (or not) with OVA. T cell activation was examined by measuring IL-2, IL-17, and IFN-g secretion. Interestingly, LPS/oxPAPC immunizations yielded substantially higher levels of all cytokines examined, as compared with immunizations with LPS alone (Fig. 4E and fig. S8C ). The ability of oxPAPC to enhance T cell activation was lost in caspase-11 or caspase-1/-11 dKO mice (Fig. 4E and fig. S8C ). Similar results were obtained measuring T cell responses 7 days after immunization ( fig. S8D ). oxPAPC therefore potentiates LPS-mediated T cell activation in a caspase-11-dependent manner.
In this study, we report two states of DC activation. The first state results from encounters with PAMPs, which induce TLRs to up-regulate several factors that promote T cell activation (23) . The second state of DCs is "hyperactive" and results from coincident encounters with PAMPs and oxPAPC, an abundant lipid at sites of tissue damage. The codetection of PAMPs and oxPAPC promotes activities elicited by the classical DC activation state but also promotes DC survival and IL-1b release. As such, hyperactive DCs are superb inducers of T cell-mediated immunity. We speculate that promoting DC hyperactivation may benefit vaccination regimens and may naturally be important during highly infectious encounters, where tissue damage and microbial products are abundant.
Our analysis also revealed caspase-11 to be an unusual PRR, which binds PAMPs and DAMPs via distinct domains and has distinct modes of activation. We consider CARD engagement by LPS to be an antimicrobial mode of caspase-11 activation, designed to expose intracellular bacteria to infiltrating neutrophils after pyroptosis (24) . In contrast, catalytic domain engagement by oxPAPC may be an immunoregulatory mode of caspase-11 activation, designed to promote T cell activation, specifically in DCs ( fig. S5 ). This study therefore provides a mandate to examine whether other PRRs have multiple states of activation.
